menu
    • menu

    Company profile for Promontory Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Promontory Therapeutics is a private, clinical-stage drug development company focusing on oncology therapeutics, running multiple clinical trials in the US and Europe. The company’s clinical lead, PT-112, has a pleiotropic mechanism of action and induces immunogenic cell death (ICD), leading to an adaptive immune response.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Promontory TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1350 Avenue of the Americas 23rd Floor New York, NY 10019
    Telephone
    Telephone
    (646) 380-2441
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://promontorytx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/promontory-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/PromontoryTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Promontory Gets FDA OK to Start Phase 3 Study of PT-112 in mCRPC
    Promontory Gets FDA OK to Start Phase 3 Study of PT-112 in mCRPC

    20 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/promontory-therapeutics-announces-successful-end-of-phase-2-meeting-with-us-fda-on-phase-3-registrational-study-design-for-pt-112-in-patients-with-metastatic-castration-resistant-prostate-cancer-302459819.html

    PR NEWSWIRE
    20 May 2025
    Share Share
    Promontory Therapeutics Completes Enrollment of Phase 2 Trial of PT-112
    Promontory Therapeutics Completes Enrollment of Phase 2 Trial of PT-112

    08 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/promontory-therapeutics-completes-enrollment-of-phase-2-trial-of-pt-112-in-late-line-patients-with-metastatic-castration-resistant-prostate-cancer-302083644.html

    PR NEWSWIRE
    08 Mar 2024
    Share Share
    Promontory Therapeutics to Present Data on PT-112 Mechanism of Action
    Promontory Therapeutics to Present Data on PT-112 Mechanism of Action

    26 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/promontory-therapeutics-to-present-data-on-pt-112-mechanism-of-action-at-the-society-for-immunotherapy-of-cancers-38th-annual-meeting-301968314.html

    PR NEWSWIRE
    26 Oct 2023
    Share Share
    Promontory Therapeutics Presents Data on the Molecular Effects of PT-112
    Promontory Therapeutics Presents Data on the Molecular Effects of PT-112

    14 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/promontory-therapeutics-presents-data-on-the-molecular-effects-of-pt-112-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-301956747.html

    PR NEWSWIRE
    14 Oct 2023
    Share Share
    Promontory Therapeutics Announces Early Phase 2 Clinical Trial Data From PT-112
    Promontory Therapeutics Announces Early Phase 2 Clinical Trial Data From PT-112

    05 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/promontory-therapeutics-announces-early-phase-2-clinical-trial-data-from-the-national-cancer-institute-demonstrating-pt-112s-immune-activation-in-thymic-epithelial-tumors-301947973.html

    PR NEWSWIRE
    05 Oct 2023
    Share Share
    Promontory Therapeutics to Present Molecular Effects of PT-112
    Promontory Therapeutics to Present Molecular Effects of PT-112

    04 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/promontory-therapeutics-to-present-molecular-effects-of-pt-112-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-301946624.html

    PR NEWSWIRE
    04 Oct 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search